Seagen’s Acquisition: EU Approval And Potential Upside

Summary:

  • Seagen Inc.’s acquisition by Pfizer Inc. has received unconditional approval from the European antitrust regulator.
  • The deal is expected to be neutral to slightly accretive to Pfizer’s EPS and has a potential upside of 6.21% for investors.
  • The absence of objections from the European regulator bodes well for treatment by other regulators, but there is still a risk of deal failure.

Pfizer COVID-19 Vaccine Data Shows 90 Percent Effective Rate

David Dee Delgado

Seagen Inc. (NASDAQ:SGEN) is being acquired by Pfizer Inc. (NYSE:PFE). The European antitrust regulator just approved the $43 billion deal unconditionally. The deal has received a second request from the


Analyst’s Disclosure: I/we have a beneficial long position in the shares of SGEN either through stock ownership, options, or other derivatives. I wrote this article myself, and it expresses my own opinions. I am not receiving compensation for it (other than from Seeking Alpha). I have no business relationship with any company whose stock is mentioned in this article.

Seeking Alpha’s Disclosure: Past performance is no guarantee of future results. No recommendation or advice is being given as to whether any investment is suitable for a particular investor. Any views or opinions expressed above may not reflect those of Seeking Alpha as a whole. Seeking Alpha is not a licensed securities dealer, broker or US investment adviser or investment bank. Our analysts are third party authors that include both professional investors and individual investors who may not be licensed or certified by any institute or regulatory body.


Check out the Special Situation Investing report if you are interested in uncorrelated returns. We look at special situations like spin-offs, share repurchases, rights offerings and M&A events like Celgene. Ideas like this are especially interesting in the current late stages of the economic cycle.

Leave a Reply

Your email address will not be published. Required fields are marked *